Methodological Gaps in Economic Evaluations of ...

By João L. Carapinha

March 10, 2026

Economic evaluations of vaccines targeting multi-disease combinations, such as hepatitis A/B or measles-mumps-rubella (MMR), reveal critical methodological shortcomings in this
HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic...
BIC LEN HIV Treatment: New Single-Tablet Regimen Shows Promising Results in A...
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM
National HealthTech Access: Transforming NHS Adoption and Equity
Launch of TrumpRx Drug Pricing: Savings on Essential Medications